Prosensa Files F-3 SEC Mixed Shelf Registration For Up To $150 Million

Prosensa Files F-3 SEC Mixed Shelf Registration For Up To $150 Million

Leiden, The Netherlands, July 7, 2014 (GLOBE NEWSWIRE) -- Prosensa Holding
N.V. (NASDAQ: RNA) the Dutch biopharmaceutical company focusing on rare
diseases with a high unmet medical need, today confirmed that on July 3 (one
year following the closing of its IPO), it filed a shelf registration
statement with the US Securities and Exchange Commission. The filing of the
registration statement is not an offering to sell securities and is intended
to enable Prosensa the flexibility to raise up to $150 million in one or more
offerings while the shelf registration statement is effective, if the company
chooses to do so. The specific terms of any securities that the Company may
offer, if it chooses to do so, will be determined at the time of such offering
and will be described in a separately filed prospectus supplement at the time
of such offering. The shelf registration statement also includes the shares of
Prosensa's three largest shareholders. There are no immediate plans to offer
or sell securities under the shelf registration statement.

A registration statement relating to these securities has been filed with the
Securities and Exchange Commission but has not yet become effective. These
securities may not be sold nor may offers to buy be accepted prior to the time
the registration statement becomes effective. This press release shall not
constitute an offer to sell or the solicitation of an offer to buy these
securities, nor shall there be any sale of these securities in any state or
jurisdiction in which such offer, solicitation or sale would be unlawful prior
to registration or qualification under the securities laws of any such state
or jurisdiction.

Any offer of these securities will be made solely by means of the prospectus
included in the registration statement and any prospectus supplement that may
be issued with respect to such offering. When available, copies of the
prospectus and any accompanying prospectus supplement relating to and
describing the terms of the offering may be obtained from Prosensa Holding
N.V., J.H. Oortweg 21, 2333 CHLeiden, The Netherlands, Attention: Celia
Economides; c.economides@prosensa.nl.

About Prosensa Holding N.V.

Prosensa (NASDAQ: RNA) is a Dutch biotechnology company engaged in the
discovery and development of RNA-modulating therapeutics for the treatment of
genetic disorders. Its primary focus is on rare neuromuscular and
neurodegenerative disorders with a large unmet medical need, including
Duchenne muscular dystrophy, Myotonic dystrophy and Huntington's
disease.www.prosensa.com

About DMD

Duchenne muscular dystrophy (DMD) is a severely debilitating childhood
neuromuscular disease that affects up to 1 in 3,500 live male births. This
rare disease is caused by mutations in the dystrophin gene, resulting in the
absence or defect of the dystrophin protein. As a result, patients suffer from
progressive loss of muscle strength, often rendering them wheelchair-bound
before the age of 12. Respiratory and cardiac muscle can also be affected by
the disease and most patients die in early adulthood due to respiratory and
cardiac failure.

Forward Looking Statement

This press release contains certain forward-looking statements. All
statements, other than statements of historical facts, contained in this press
release, including statements regarding any future offering under the shelf
registration statement are forward-looking statements. Such forward-looking
information involves risks and uncertainties that could significantly affect
expected results. These risks and uncertainties are discussed in the
Company's SEC filings, including, but not limited to, the Company's annual
report on Form 20-F. In addition, any forward-looking statements represent our
views only as of today and should not be relied upon as representing our views
as of any subsequent date. While we may elect to update these forward-looking
statements at some point in the future, we specifically disclaim any
obligation to do so, even if our views change.

CONTACT: Prosensa Holding N.V.
         Celia Economides
         M: +1 917.941.9059
         M: +31 (0) 64 85 18 182 (NL)
         E: c.economides@prosensa.nl

Prosensa Holding B.V. Logo
 
Press spacebar to pause and continue. Press esc to stop.